跳到正文
原文
MedPage Today·· 12 天前精选AI 评分70

烟草市场的迷宫:尼古丁产品的风险与沟通

Lost in the Labyrinth of Nicotine Products

AI 导读

文章指出,美国烟草市场产品种类繁多且信息复杂,建议医疗从业者和公共卫生机构应提供透明的沟通,帮助公众理解不同产品的风险差异,避免误导。

推荐理由

文章分析了当前烟草市场的复杂性,强调了透明沟通的重要性。

正文 · 原文

— Clinicians need a better way to talk about nicotine risk

by Ying Zhang, MSPH, Andy Tan, PhD, MBBS, MPH, MBA, and Meghan Moran, PhD

November 8, 2026 • 4 min read

Americans increasingly navigate a fast-changing marketplace of nicotine and tobacco products. Walk into a convenience store today and you will encounter a dizzying array of products: cigarettes, e-cigarettes, nicotine pouches, smokeless tobacco, snus, and heated tobacco products, often sold in bright packaging and flavors designed to appeal.

Accompanying this is a confusing information environment. Public health campaigns warn about the dangers of using any tobacco, while the FDA has authorized certain products to carry a modified-risk claim. News stories describe an epidemic of youth vaping, while research reports find that e-cigarettes can help adult smokers quit. Marketing of nicotine and tobacco products often features young, healthy-looking individuals engaged in athletic activities and promises "smoke-free" or "cleaner" experiences, while warnings on products emphasize the dangers of use.

A recent op-ed asserting that the risk of nicotine and tobacco products operates on a continuum illustrates the confusion. Although the byline was attributed to Tom Price, MD, former HHS secretary, a disclosure at the end of the article indicates that it was, in fact, produced in partnership with and paid for by PMI Corporate Services Inc. (Philip Morris International -- a major tobacco company).

While no tobacco products are completely safe, the FDA has recognized that combustible tobacco products (i.e., products that are burned and smoked) like cigarettes pose the greatest health risks and that noncombustible products generally fall lower on the risk spectrum. Reflecting this, the agency has permitted certain products to be marketed with a modified-risk claim that using those products instead of cigarettes reduces the risk of several serious diseases.

As researchers in tobacco communication and regulatory science, we argue that public health agencies and healthcare practitioners have a responsibility to help people navigate this complicated environment. As the nicotine and tobacco marketplace changes, so should our communication about the harm of these products. Individuals in the U.S. are confronted with an assortment of seemingly conflicting messages about nicotine and tobacco products. It is easy to see why people might not fully understand that different products present varying harms.

For someone who does not use any nicotine or tobacco products, the advice is straightforward: Don't start. Nicotine is addictive, and products containing nicotine present a variety of risks, including cardiovascular diseases. For someone who smokes cigarettes, quitting entirely is the best option, and approved treatments such as nicotine patches, gum, and lozenges, and prescription medications should generally be considered as first-line approaches.

But real life is rarely so tidy. Some people try repeatedly to quit and cannot. Others are not yet ready to give up using nicotine and tobacco products. For them, understanding the differences in risk between continuing to smoke cigarettes and using nicotine and tobacco products that are not burnt can impact their health. Eliminating cigarette smoke exposure, even if someone continues to use nicotine and tobacco, can lead to a meaningful reduction in harm.

Clinicians have recommended considering e-cigarettes as a smoking cessation tool for patients who smoke. However, as the marketplace expands far beyond e-cigarettes, doctors, public health agencies, and other trusted voices should be prepared to explain a continuum of risk among various nicotine and tobacco products rather than centering on any single product. This does not mean handing smokers a shopping list. It does not mean calling vapes, nicotine pouches, or smokeless tobacco harmless. And it certainly does not mean encouraging people who do not currently use nicotine to start.

It means being transparent about what we know: Cigarettes are extraordinarily dangerous, and nicotine is what makes them so hard to quit. Some other products can deliver nicotine, but carry substantially lower risks to one's health. Switching completely matters, and using cigarettes alongside another product does not deliver the same risk reduction.

To be clear, we do not know for certain the best way to deliver the information to people who smoke. It could be conversations between healthcare providers and their patients, public education campaigns, a trusted source anyone can consult easily, or some combination of the above. Each approach has trade-offs in reach, cost, and the risk of unintended consequences. What we need is evidence on which approaches help smokers understand relative risk without encouraging nicotine and tobacco product use among people who otherwise would not start.

One key principle is ensuring that whatever the format this communication takes, the information comes from credible and independent sources with no stake in selling these products.

This conversation cannot wait because people are already hearing claims in ads and on social media about reduced harm of certain nicotine and tobacco products. Influencers portray nicotine pouches as a lifestyle, with talk of "upper deckies" and what it means to be a "Zynner." Increasingly, people will see modified-risk claims that the FDA has authorized. If health professionals respond with silence or oversimplified messages, the tobacco industry, social media, and word of mouth will fill the gap. Communication revolving around nicotine and tobacco product harm should help people make sense of the growing array of products and understand how each one works and what risks they carry.

Some worry that acknowledging reduced-risk products sounds like endorsing the tobacco industry. Given the industry's history of deceiving consumers about the risks presented by tobacco, skepticism is warranted. But withholding meaningful information, supported by evidence from the scientific community, on the risk differences is not the answer.

We can hold two ideas at once: No nicotine or tobacco product is safe, and some products are far more dangerous than others. For decades, public health has taught Americans how dangerous cigarettes are, and we should not undermine that achievement. But an evolving marketplace demands an evolving message -- one that tells people not only what to avoid, but how products differ, what switching can and cannot accomplish, and where the evidence remains uncertain. Americans navigating an increasingly complicated nicotine marketplace deserve an accurate roadmap to protect the public's health.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

来源:MedPage Today · medpagetoday.com